[1] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet. 2018, 391(10127): 1301-1314.
[2] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin. 2020, 70(1): 7-30.
[3] Civan J M. Management of Small Hepatocellular Carcinoma[J]. Radiology. 2016, 279(2): 651-652.
[4] Hyun D, Cho S K, Shin S W, et al. Treatment of Small Hepatocellular Carcinoma (</=2 cm) in the Caudate Lobe with Sequential Transcatheter Arterial Chemoembolization and Radiofrequency Ablation[J]. Cardiovasc Intervent Radiol. 2016, 39(7): 1015-1022.
[5] Llovet J M, Bruix J. Molecular targeted therapies in hepatocellular carcinoma[J]. Hepatology. 2008, 48(4): 1312-1327.
[6] Giannini E G, Savarino V. Platelet count and survival of patients with compensated cirrhosis and small hepatocellular carcinoma treated with surgery[J]. Hepatology. 2014, 59(4): 1649.
[7] Tsujita E, Yamashita Y, Takeishi K, et al. The clinicopathological impact of gross classification on solitary small hepatocellular carcinoma[J]. Hepatogastroenterology. 2013, 60(127): 1726-1730.
[8] Dai H, Cui D, Li D, et al. Hepatic abscess with hepatobronchial fistula following percutaneous radiofrequency ablation for hepatocellular carcinoma: A case report[J]. Oncol Lett. 2015, 9(5): 2289-2292.
[9] Tam W L, Weinberg R A. The epigenetics of epithelial-mesenchymal plasticity in cancer[J]. Nat Med. 2013, 19(11): 1438-1449.
[10] Liu J, Cui X, Jiang J, et al. Uncoordinated expression of DNA methylation-related enzymes in human cancer[J]. Epigenetics Chromatin. 2017, 10(1): 61.
[11] Storebjerg T M, Strand S H, Hoyer S, et al. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer[J]. Clin Epigenetics. 2018, 10(1): 105.
[12] Kantidze O L, Razin S V. 5-hydroxymethylcytosine in DNA repair: A new player or a red herring?[J]. Cell Cycle. 2017, 16(16): 1499-1501.
[13] Tucker D W, Getchell C R, Mccarthy E T, et al. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer[J]. Clin Cancer Res. 2018, 24(6): 1389-1401.
[14] Wielscher M, Liou W, Pulverer W, et al. Cytosine 5-Hydroxymethylation of the LZTS1 Gene Is Reduced in Breast Cancer[J]. Transl Oncol. 2013, 6(6): 715-721.
[15] Jeschke J, Collignon E, Fuks F. Portraits of TET-mediated DNA hydroxymethylation in cancer[J]. Curr Opin Genet Dev. 2016, 36: 16-26.
[16] Wang K C, Kang C H, Tsai C Y, et al. Ten-eleven translocation 1 dysfunction reduces 5-hydroxymethylcytosine expression levels in gastric cancer cells[J]. Oncol Lett. 2018, 15(1): 278-284.
[17] Lewis K A, Tollefsbol T O. The influence of an epigenetics diet on the cancer epigenome[J]. Epigenomics. 2017, 9(9): 1153-1155.
[18] Sowers J L, Johnson K M, Conrad C, et al. The role of inflammation in brain cancer[J]. Adv Exp Med Biol. 2014, 816: 75-105.
[19] Lin J R, Qin H H, Wu W Y, et al. Vitamin C protects against UV irradiation-induced apoptosis through reactivating silenced tumor suppressor genes p21 and p16 in a Tet-dependent DNA demethylation manner in human skin cancer cells[J]. Cancer Biother Radiopharm. 2014, 29(6): 257-264.
[20] Liu J, Jiang J, Mo J, et al. Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma[J]. Hepatology. 2019, 69(1): 196-208.
[21] Sajadian S O, Ehnert S, Vakilian H, et al. Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma[J]. Clin Epigenetics. 2015, 7: 98.
[22] Hlady R A, Sathyanarayan A, Thompson J J, et al. Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma[J]. Hepatology. 2019, 69(2): 639-652.
[23] Lei J C, Gong W D, Zhao Y, et al. [The influences of Tet system on activity and tissue specificity of HBV Cp.][J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2009, 25(12): 1103-1105.
[24] Ogura N, Watashi K, Noguchi T, et al. Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line[J]. Biochem Biophys Res Commun. 2014, 452(3): 315-321.
[25] Cheng X J, Lin J C, Tu S P. Etiology and Prevention of Gastric Cancer[J]. Gastrointest Tumors. 2016, 3(1): 25-36.
[26] Afify S M, Hassan G, Osman A, et al. Metastasis of Cancer Stem Cells Developed in the Microenvironment of Hepatocellular Carcinoma[J]. Bioengineering (Basel). 2019, 6(3).
[27] Liu J, Jiang J, Mo J, et al. Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma[J]. Hepatology. 2019, 69(1): 196-208.
[28] Chatterjee B, Lin M H, Chen C C, et al. DNA Demethylation by DNMT3A and DNMT3B in vitro and of Methylated Episomal DNA in Transiently Transfected Cells[J]. Biochim Biophys Acta Gene Regul Mech. 2018, 1861(11): 1048-1061.
[29] Vertino P M, Wade P A. R loops: lassoing DNA methylation at CpGi[J]. Mol Cell. 2012, 45(6): 708-709.
[30] Hasegawa R, Fujiwara K, Obinata D, et al. Identification of frequent differentially methylated region in sporadic bladder cancers[J]. Urol Int. 2015, 94(4): 479-484.
[31] Makise N, Sekimizu M, Kubo T, et al. Extraskeletal osteosarcoma: MDM2 and H3K27me3 analysis of 19 cases suggest disease heterogeneity[J]. Histopathology. 2018, 73(1): 147-156.
[32] Katz L M, Hielscher T, Liechty B, et al. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence[J]. Acta Neuropathol. 2018, 135(6): 955-963.
[33] Iwagawa T, Watanabe S. Molecular mechanisms of H3K27me3 and H3K4me3 in retinal development[J]. Neurosci Res. 2019, 138: 43-48.
[34] Mallol A, Guirola M, Payer B. PRDM14 controls X-chromosomal and global epigenetic reprogramming of H3K27me3 in migrating mouse primordial germ cells[J]. Epigenetics Chromatin. 2019, 12(1): 38.
[35] Lee E, Wang J, Jung Y, et al. Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer[J]. J Cell Biochem. 2018, 119(4): 3697-3705.
[36] Hayashi A, Yamauchi N, Shibahara J, et al. Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior[J]. PLoS One. 2014, 9(3): e91330.
[37] Hlady R A, Sathyanarayan A, Thompson J J, et al. Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma[J]. Hepatology. 2019, 69(2): 639-652.
[38] Saloustros E, Mavroudis D. Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis[J]. Future Oncol. 2010, 6(2): 209-219.
[39] Gillanders W E, Mikhitarian K, Hebert R, et al. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study[J]. Ann Surg. 2004, 239(6): 828-837, 837-840.
[40] Lee J I, Lee J W, Kim J M, et al. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers[J]. World J Gastroenterol. 2012, 18(34): 4751-4757.
[41] Lee K, Lee K B, Jung H Y, et al. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas[J]. BMC Cancer. 2017, 17(1): 441.
[42] Yoon S O, Kim Y T, Jung K C, et al. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients[J]. Lung Cancer. 2011, 71(2): 209-216.